NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis

NYSE:NMR • US65535H2085

9.23 USD
-0.16 (-1.7%)
At close: Feb 20, 2026
9.28 USD
+0.05 (+0.54%)
After Hours: 2/20/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NMR. NMR was compared to 238 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year NMR was profitable.
  • In the past year NMR had a positive cash flow from operations.
  • In the past 5 years NMR has always been profitable.
  • The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
NMR Yearly Net Income VS EBIT VS OCF VS FCFNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B 1T -1T -1.5T

1.2 Ratios

  • With a Return On Assets value of 0.61%, NMR is not doing good in the industry: 72.57% of the companies in the same industry are doing better.
  • NMR has a Return On Equity of 10.62%. This is in the better half of the industry: NMR outperforms 62.45% of its industry peers.
  • NMR's Return On Invested Capital of 0.68% is on the low side compared to the rest of the industry. NMR is outperformed by 67.09% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.31%.
  • The 3 year average ROIC (0.42%) for NMR is below the current ROIC(0.68%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROIC 0.68%
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
NMR Yearly ROA, ROE, ROICNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • With a Profit Margin value of 8.05%, NMR is not doing good in the industry: 67.51% of the companies in the same industry are doing better.
  • NMR's Profit Margin has declined in the last couple of years.
  • NMR has a worse Operating Margin (11.60%) than 63.29% of its industry peers.
  • NMR's Operating Margin has declined in the last couple of years.
  • NMR has a Gross Margin (43.38%) which is in line with its industry peers.
  • NMR's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
NMR Yearly Profit, Operating, Gross MarginsNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, NMR has less shares outstanding
  • Compared to 5 years ago, NMR has less shares outstanding
  • NMR has a better debt/assets ratio than last year.
NMR Yearly Shares OutstandingNMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NMR Yearly Total Debt VS Total AssetsNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10T 20T 30T 40T 50T

2.2 Solvency

  • Based on the Altman-Z score of -0.22, we must say that NMR is in the distress zone and has some risk of bankruptcy.
  • NMR has a worse Altman-Z score (-0.22) than 80.59% of its industry peers.
  • NMR has a Debt/Equity ratio of 10.65. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 10.65, NMR is doing worse than 87.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Altman-Z -0.22
ROIC/WACCN/A
WACCN/A
NMR Yearly LT Debt VS Equity VS FCFNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5T 10T

2.3 Liquidity

  • A Current Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • With a Current ratio value of 0.27, NMR is not doing good in the industry: 81.86% of the companies in the same industry are doing better.
  • NMR has a Quick Ratio of 0.27. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of NMR (0.27) is worse than 81.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
NMR Yearly Current Assets VS Current LiabilitesNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T 25T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 9.84% over the past year.
  • Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
  • NMR shows a decrease in Revenue. In the last year, the revenue decreased by -4.21%.
  • The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.79% on average over the next years.
  • NMR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.11% yearly.
EPS Next Y10.55%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
EPS Next 5YN/A
Revenue Next Year-15.08%
Revenue Next 2Y-7.01%
Revenue Next 3Y-4.11%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NMR Yearly Revenue VS EstimatesNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
NMR Yearly EPS VS EstimatesNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • NMR is valuated reasonably with a Price/Earnings ratio of 11.26.
  • Based on the Price/Earnings ratio, NMR is valued a bit cheaper than 62.03% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, NMR is valued rather cheaply.
  • NMR is valuated reasonably with a Price/Forward Earnings ratio of 11.39.
  • Based on the Price/Forward Earnings ratio, NMR is valued a bit cheaper than the industry average as 63.29% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. NMR is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.26
Fwd PE 11.39
NMR Price Earnings VS Forward Price EarningsNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than 69.20% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.54
NMR Per share dataNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.07
PEG (5Y)1.03
EPS Next 2Y3.07%
EPS Next 3Y3.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 3.50%, NMR has a reasonable but not impressive dividend return.
  • NMR's Dividend Yield is comparable with the industry average which is at 6.09.
  • NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 3.5%

5.2 History

  • On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
  • NMR has paid a dividend for at least 10 years, which is a reliable track record.
  • The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
NMR Yearly Dividends per shareNMR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

5.3 Sustainability

  • NMR pays out 45.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP45.53%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
NMR Yearly Income VS Free CF VS DividendNMR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T
NMR Dividend Payout.NMR Dividend Payout, showing the Payout Ratio.NMR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (2/20/2026, 8:04:00 PM)

After market: 9.28 +0.05 (+0.54%)

9.23

-0.16 (-1.7%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-30
Earnings (Next)05-10
Inst Owners41.8%
Inst Owner Change5.65%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap27.08B
Revenue(TTM)4.63T
Net Income(TTM)370.05B
Analysts72.31
Price Target8.31 (-9.97%)
Short Float %0.09%
Short Ratio1.89
Dividend
Industry RankSector Rank
Dividend Yield 3.5%
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP45.53%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.01%
PT rev (3m)12.1%
EPS NQ rev (1m)-7.96%
EPS NQ rev (3m)29.26%
EPS NY rev (1m)0.87%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE 11.26
Fwd PE 11.39
P/S 0.91
P/FCF N/A
P/OCF 6.62
P/B 1.2
P/tB 1.23
EV/EBITDA 21.54
EPS(TTM)0.82
EY8.88%
EPS(NY)0.81
Fwd EY8.78%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)1.39
OCFY15.1%
SpS10.11
BVpS7.67
TBVpS7.5
PEG (NY)1.07
PEG (5Y)1.03
Graham Number11.9
Profitability
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROCE 1.68%
ROIC 0.68%
ROICexc 0.76%
ROICexgc 0.77%
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
FCFM N/A
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score7
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Debt/EBITDA 62.4
Cap/Depr 1450.41%
Cap/Sales 19.46%
Interest Coverage 0.21
Cash Conversion 106.5%
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -0.22
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
EPS Next Y10.55%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%
Revenue Next Year-15.08%
Revenue Next 2Y-7.01%
Revenue Next 3Y-4.11%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year26591.8%
EBIT Next 3Y531.02%
EBIT Next 5YN/A
FCF growth 1Y58.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.88%
OCF growth 3YN/A
OCF growth 5YN/A

NOMURA HOLDINGS INC-SPON ADR / NMR FAQ

Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?

ChartMill assigns a fundamental rating of 3 / 10 to NMR.


What is the valuation status of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.


Can you provide the profitability details for NOMURA HOLDINGS INC-SPON ADR?

NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.


What is the financial health of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.


What is the earnings growth outlook for NOMURA HOLDINGS INC-SPON ADR?

The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 10.55% in the next year.